Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Retained Earnings (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Retained Earnings for 16 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 48.35% to -$1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 billion, a 48.35% decrease, with the full-year FY2025 number at -$1.1 billion, down 48.35% from a year prior.
  • Retained Earnings was -$1.1 billion for Q4 2025 at Myriad Genetics, down from -$100000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$100000.0 in Q2 2025 to a low of -$1.1 billion in Q4 2025.
  • A 5-year average of -$339.1 million and a median of -$273.0 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 13377.36% in 2024, then surged 99.99% in 2025.
  • Myriad Genetics' Retained Earnings stood at -$254.2 million in 2021, then soared by 96.5% to -$8.9 million in 2022, then plummeted by 6973.03% to -$629.5 million in 2023, then dropped by 20.22% to -$756.8 million in 2024, then tumbled by 48.35% to -$1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Retained Earnings are -$1.1 billion (Q4 2025), -$100000.0 (Q3 2025), and -$100000.0 (Q2 2025).